NeuBase Therapeutics, Inc.

DB:O7P Stock Report

Market Cap: €1.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NeuBase Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Todd Branning

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2.4yrs
CEO ownership0.04%
Management average tenureno data
Board average tenure3.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Todd Branning's remuneration changed compared to NeuBase Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-US$25m

Dec 31 2022n/an/a

-US$30m

Sep 30 2022US$922kUS$311k

-US$34m

Compensation vs Market: Insufficient data to establish whether Todd's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Insufficient data to compare Todd's compensation with company performance.

CEO

Todd Branning (54 yo)

2.4yrs

Tenure

US$922,445

Compensation

Mr. Todd P. Branning serves as an Interim Chief Executive Officer since January 16, 2024 and Chief Financial Officer of NeuBase Therapeutics, Inc. since January 2022 and serves as its Secretary. He joined...

Board Members

NamePositionTenureCompensationOwnership
Dietrich Stephan
Founder4.9yrsUS$1.15m6.14%
€ 78.5k
Dov Goldstein
Independent Chairperson4.9yrsUS$74.42k0.040%
€ 510.9
Eric Richman
Independent Director4.9yrsUS$68.38k0.060%
€ 765.3
George Church
Chairperson of Gene Editing Advisory Board & Member of Scientific Advisory Board1.1yrsno datano data
Steven Dowdy
Member of Gene Editing & Scientific Advisory Board4.7yrsno datano data
James Coull
Member of Gene Editing Advisory Board1.1yrsno datano data
Randy Davis
Member of Scientific Advisory Board3.6yrsno datano data
Danith Ly
Member of Advisory Boardno datano datano data
Robert Friedlander
Chair of Scientific Advisory Boardno datano datano data
Peter Nielsen
Member of Gene Editing & Scientific Advisory Board3.7yrsno datano data
Eriks Rozners
Member of Gene Editing & Scientific Advisory Board3.6yrsno datano data
Gerald Mcdougall
Independent Director3.1yrsUS$59.79k0%
€ 0

3.6yrs

Average Tenure

57yo

Average Age

Experienced Board: O7P's board of directors are considered experienced (3.6 years average tenure).